Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 186 participants.
Also called NCT06962098
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 186 participants
- Sponsor
- Aptabio Therapeutics, Inc.
- Registry
-
NCT06962098
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06962098. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-26 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
- Acronym
- PROMISS-DKD
- Condition
- Diabetic Kidney Disease (DKD)
- Intervention (Drug)
- Isuzinaxib
- Intervention (Drug)
- Placebo
- Lead sponsor
- Aptabio Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct06962098- Content hash
52beacd42bfca174cae49e7f5d3b40d3949c9b139f7672f5818c6ac70e162abf